Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20126630 | 1.00 | KDM4E (0.31) | KDM4EALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL19134414 | 0.96 | KDM4E (0.30) | KDM4EALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL15937171 | 0.96 | KDM4E (0.30) | KDM4EALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL17351811 | 0.88 | NPC1L1 (0.30) | — | |
| SCHEMBL17359167 | 0.88 | — | — | |
| SCHEMBL20126629 | 0.85 | — | — | |
| SCHEMBL17359193 | 0.85 | ALDH1A1 (0.35) | KDM4EALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL17359157 | 0.85 | — | — | |
| SCHEMBL20126623 | 0.85 | GRIN2B (0.32) | — | |
| SCHEMBL15937153 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127430-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2018-05-10 | — | — | US | disclosed |
| US-9708335-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | Apytinyx Inc. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20150368254-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127430-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | KDM4E 2649/4885ALDH1A1 2288/4885SMN1; SMN2 913/4885 |
| US-20150368254-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | KDM4E 2649/4885ALDH1A1 2288/4885SMN1; SMN2 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.